Beyond the storm—subacute toxicities and late effects in children receiving CAR T cells
H Shalabi, J Gust, A Taraseviciute, PL Wolters… - Nature Reviews …, 2021 - nature.com
As clinical advances with chimeric antigen receptor (CAR) T cells are increasingly described
and the potential for extending their therapeutic benefit grows, optimizing the …
and the potential for extending their therapeutic benefit grows, optimizing the …
Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper
N Gagelmann, A Sureda, S Montoto, J Murray… - The Lancet …, 2022 - thelancet.com
Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach
in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell …
in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell …
DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality
K Wudhikarn, M Pennisi, M Garcia-Recio… - Blood …, 2020 - ashpublications.org
Cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome
are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In …
are the most notable toxicities of CD19 chimeric antigen receptor (CAR) T-cell therapy. In …
[HTML][HTML] Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy
J Ruark, E Mullane, N Cleary, A Cordeiro… - Biology of Blood and …, 2020 - Elsevier
ABSTRACT CD19-targeted chimeric antigen receptor (CAR) modified T cell immunotherapy
is a novel treatment with promising results in patients with relapsed/refractory lymphoid …
is a novel treatment with promising results in patients with relapsed/refractory lymphoid …
Health-related quality of life with idecabtagene vicleucel in relapsed and refractory multiple myeloma
Abstract Idecabtagene vicleucel (ide-cel), a B-cell maturation antigen–directed chimeric
antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class …
antigen receptor T cell therapy, showed deep, durable responses in patients with triple-class …
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global …
Background The ELIANA trial showed that 61 (81%) of 75 paediatric and young adult
patients with relapsed or refractory B-cell acute lymphoblastic leukaemia achieved overall …
patients with relapsed or refractory B-cell acute lymphoblastic leukaemia achieved overall …
Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant
S Sidana, AC Dueck, G Thanarajasingam… - … and cellular therapy, 2022 - Elsevier
There are limited data on patient experience after chimeric antigen receptor (CAR) T-cell
therapy, especially in comparison to autologous and allogeneic transplantation, which are …
therapy, especially in comparison to autologous and allogeneic transplantation, which are …
Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments
Abstract Purpose of Review The chimeric antigen receptor (CAR) T-cell therapy is currently
changing the landscape of hematologic malignancies with multiple FDA-approved cell …
changing the landscape of hematologic malignancies with multiple FDA-approved cell …
[HTML][HTML] Late effects after chimeric antigen receptor T cell therapy for lymphoid malignancies
Chimeric antigen receptor T cell (CAR T) therapy has changed the treatment landscape of
relapsed/refractory lymphoid malignancies. With an expanding pool of post–CAR T cell …
relapsed/refractory lymphoid malignancies. With an expanding pool of post–CAR T cell …
[HTML][HTML] Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies
XS Wang, SA Srour, M Whisenant, IM Subbiah… - … and Cellular Therapy, 2021 - Elsevier
Chimeric antigen receptor (CAR) T cell therapy is being increasingly used to treat patients
with advanced hematologic malignancies; however, the symptoms related to standard of …
with advanced hematologic malignancies; however, the symptoms related to standard of …